Background
Methods
Study design
Participants
Patients included | Patients excluded | MWU | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
value |
n
| Mean ± SD | Min | Max | % |
n
| Mean ± SD | Min | Max |
p
| ||
Age at onset (years) | 74 | 6.79 ± 1.18 | 3.00 | 8.00 | 419 | 6.66 ± 1.38 | 0.10 | 8.0 | 0.335 | |||
≤6 | 18 | 24.3 | ||||||||||
Initial evaluation | Age (years) | 74 | 7.50 ± 1.28 | 3.50 | 9.50 | 419 | 7.56 ± 1.47 | 0.75 | 10.58 | 0.479 | ||
BMI (kg/m2) | 74 | 17.40 ± 1.97 | 14.73 | 23.84 | 410 | 17.48 ± 2.20 | 12.21 | 25.45 | 0.673 | |||
BMI (SDS) | 74 | 0.1 ± 1.40 | −2.00 | 4.60 | 410 | 1.29 ± 1.59 | −2.4 | 6.6 | 0.958 | |||
≥2 | 7 | 9.4 | ||||||||||
Growth rate the year before (cm) | 70 | 7.55 ± 1.57 | 5.00 | 13.00 | 374 | 7.80 ± 2.17 | 2.00 | 24.00 | 0.593 | |||
Growth rate the year before (SDS) | 70 | 1.89 ± 1.80 | −1.1 | 6.6 | 374 | 2.32 ± 2.38 | −4.67 | 12.94 | 0.489 | |||
≥2 | 32 | 45.7 | ||||||||||
Height (cm) | 74 | 130.46 ± 9.57 | 101 | 146.5 | 419 | 130.63 ± 11.59 | 68.0 | 155.0 | 0.521 | |||
Height (SDS) | 74 | 2.06 ± 1.43 | −1.31 | 6.18 | 419 | 2.1 ± 1.3 | −2.9 | 5.3 | 0.913 | |||
Bone age (years) | 73 | 8.7 ± 1.6 | 4 | 11 | ||||||||
Difference between bone and chronological ages (years) | 73 | 1.23 ± 1.25 | −0.90 | 5.50 | 405 | 1.3 ± 1.3 | −2.5 | 6 | 0.787 | |||
≥2 | 24 | 32.9 | ||||||||||
Uterus length (mm) | 47 | 35.03 ± 8.02 | 21.00 | 58.00 | 223 | 36.19 ± 8.97 | 16.00 | 75.00 | 0.463 | |||
≥35 | 23 | 48.9 | ||||||||||
Basal LH concentration (IU/L) | 65 | 0.67 ± 0.83 | 0.10 | 5.00 | 334 | 0.84 ± 1.58 | 0.00 | 20.20 | 0.341 | |||
Basal FSH concentration (IU/L) | 64 | 2.04 ± 1.63 | 0.40 | 7.00 | 335 | 2.95 ± 2.09 | 0.20 | 10.00 |
0.001
| |||
LH peak (IU/L) | 74 | 8.95 ± 10.55 | 0.60 | 46.00 | 419 | 12.16 ± 14.90 | 0.20 | 101.0 | 0.059 | |||
FSH peak (IU/L) | 74 | 11.40 ± 5.96 | 0.80 | 36.50 | 419 | 12.84 ± 6.96 | 1.10 | 62.00 |
0.045
| |||
LH/FSH peak ratio | 74 | 0.96 ± 1.35 | 0.09 | 7.62 | 419 | 0.95 ± 1.07 | 0.04 | 9.83 | 0.170 | |||
≥0.66 | 27 | 36.5 | ||||||||||
Estradiol (pg/mL) | 74 | 13.4 ± 14.45 | 2.00 | 88.00 | ||||||||
≥15 | 20 | 27 | ||||||||||
BAP (μg/L) | 62 | 78.5 ± 30.3 | 32.1 | 167.2 | ||||||||
CTX (pg/L) | 69 | 5540 ± 6438.9 | 682 | 54,627 | ||||||||
Untreated patients | 49 | 66.2 | ||||||||||
Growth rate 6 months following initial evaluation (cm) | 28 | 3.8 ± 1.1 | 2 | 6 | ||||||||
Growth rate 6 months following initial evaluation (SDS) | 28 | 2 ± 2.5 | −2.25 | 8 | ||||||||
Growth rate the year following initial evaluation (cm) | 16 | 7.6 ± 1.8 | 4.7 | 11 | ||||||||
Growth rate the year following initial evaluation (SDS) | 16 | 2.1 ± 2.2 | −1.5 | 6.6 | ||||||||
≥2 | 8 | 50 | ||||||||||
Adult height (cm) | 21 | 163.7 ± 6.4 | 151 | 178 | ||||||||
Adult height (SDS) | 21 | 0.1 ± 1.1 | −2.2 | 2.6 | ||||||||
Difference between target and adult heights (cm) | 19 | −1.2 ± 3.7 | −7 | 4.5 | ||||||||
≥5 | 0 | 0 |
Methods
Statistical analysis
Results
Characteristics at initial evaluation (Table 1)
Correlations (Table 2)
BAP | CTX | ||||||||
---|---|---|---|---|---|---|---|---|---|
n | r | IC 95% |
p
|
n
| r | IC 95% |
p
| ||
All patients | Age at onset of puberty (years) | 62 | −0.15 | −0.40; 0.11 | 0.232 | 69 | 0.05 | −0.2; 0.29 | 0.711 |
Age at initial evaluation (years) | 62 | −0.17 | − 0.41; 0.09 | 0.180 | 69 | 0.01 | −0.23; 0.25 | 0.941 | |
BMI (SDS) | 62 | 0.04 | −0.22; 0.29 | 0.752 | 69 | −0.04 | −0.28; 0.21 | 0.761 | |
Growth rate the year before initial evaluation (cm) | 60 | 0.21 | −0.05; 0.45 | 0.100 | 65 | 0.26 | 0.01; 0.48 |
0.035
| |
Growth rate the year before initial evaluation (SDS) | 60 | 0.10 | −0.17; 0.35 | 0.446 | 65 | 0.34 | 0.09; 0.54 |
0.006
| |
Height at initial evaluation (cm) | 62 | 0,10 | −0.16; 0.35 | 0.424 | 69 | 0.09 | −0.16; .32 | 0.480 | |
Height at initial evaluation (SDS) | 62 | 0.31 | 0.06; 0.52 |
0.015
| 69 | 0.21 | −0.03; 0.43 | 0.078 | |
Bone age (years) | 61 | 0.19 | −0.08; 0.42 | 0.151 | 68 | 0.07 | −0.18; 0.31 | 0.566 | |
Difference between bone and chronological ages (years) | 61 | 0.39 | 0.15; 0.59 |
0.002
| 68 | 0.07 | −0.18; 0.31 | 0.566 | |
BAP (μg/L) | 57 | 0.19 | −0.08; 0.44 | 0.153 | |||||
Basal LH concentration (IU/L) | 58 | 0.07 | −0.20; 0.33 | 0.606 | 60 | 0.15 | −0.11; 0.4 | 0.243 | |
Basal FSH concentration (IU/L) | 57 | 0.27 | 0.00; 0.50 |
0.042
| 59 | −0.02 | −0.28; 0.24 | 0.860 | |
LH peak (IU/L) | 62 | 0.24 | −0.02; 0.47 | 0.063 | 69 | 0.12 | −0.13; 0.35 | 0.346 | |
FSH peak (IU/L) | 62 | 0.10 | −0.16; 0.35 | 0.448 | 69 | 0.01 | −0.23; 0.25 | 0.935 | |
LH/FSH peak ratio | 62 | 0.14 | −0.12; 0.39 | 0.263 | 69 | 0.10 | −0.15; 0.33 | 0.415 | |
Estradiol (pg/mL) | 62 | 0.16 | −0.10; 0.40 | 0.206 | 69 | −0.06 | −0.3; 0.19 | 0.618 | |
Untreated patients | Growth rate 6 months following initial evaluation (SDS) | 25 | 0.17 | −0.25; 0.54 | 0.406 | 24 | −0.02 | −0.43; 0.40 | 0.928 |
Growth rate the year following initial evaluation (SDS) | 13 | 0.31 | −0.31; 0.74 | 0.306 | 13 | −0.18 | −0.67; 0.43 | 0.566 | |
Adult height (cm) | 19 | 0.58 | 0.16; 0.82 |
0.009
| 17 | 0.04 | −0.46; 0.52 | 0.874 | |
Adult height (SDS) | 19 | 0.58 | 0.15; 0.82 |
0.009
| 17 | 0.04 | −0.46; 0.53 | 0.869 | |
Difference between target and adult heights (cm) | 17 | −0.19 | −0.63; 0.33 | 0.453 | 15 | −0.23 | − 0.67; 0.33 | 0.404 |